Hyperion Therapeutics Major Shareholder Sells $470,331 in Stock (HPTX)
Hyperion Therapeutics (NASDAQ:HPTX) major shareholder Highland Management Partners V unloaded 18,048 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $26.06, for a total transaction of $470,330.88. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Several analysts have recently commented on the stock. Analysts at Needham & Company reiterated a “buy” rating on shares of Hyperion Therapeutics (NASDAQ:HPTX) in a research note to investors on Thursday, August 15th. They now have a $35.00 price target on the stock, up previously from $25.00. Separately, analysts at Zacks downgraded shares of Hyperion Therapeutics (NASDAQ:HPTX) from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, August 7th. They now have a $28.20 price target on the stock. Finally, analysts at Zacks upgraded shares of Hyperion Therapeutics (NASDAQ:HPTX) from a “neutral” rating to an “outperform” rating in a research note to investors on Tuesday, July 9th. They now have a $24.30 price target on the stock.
One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $31.55.
Shares of Hyperion Therapeutics (NASDAQ:HPTX) traded up 3.58% during mid-day trading on Tuesday, hitting $26.93. 86,622 shares of the company’s stock traded hands. Hyperion Therapeutics has a one year low of $10.00 and a one year high of $27.00. The stock’s 50-day moving average is $24.9 and its 200-day moving average is $22.98. The company has a market cap of $540.9 million and a price-to-earnings ratio of 159.51.
Hyperion Therapeutics (NASDAQ:HPTX) last released its earnings data on Wednesday, August 14th. The company reported ($0.22) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.17) by $0.05. The company had revenue of $7.30 million for the quarter, compared to the consensus estimate of $2.17 million. On average, analysts predict that Hyperion Therapeutics will post $0.67 earnings per share for the current fiscal year.
Hyperion Therapeutics, Inc (NASDAQ:HPTX)is a development-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.